Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

PURPOSE: The aim of this analysis was to investigate the potential for ulixertinib (BVD-523) to prolong cardiac repolarization. The mean prolongation of the corrected QT (QTc) interval was predicted at the mean maximum drug concentrations of the recommended phase 2 dose (RP2D; 600 mg BID) and of hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendzelevski, Boaz, Ferber, Georg, Janku, Filip, Li, Bob T., Sullivan, Ryan J., Welsch, Dean, Chi, Wei, Jackson, Jeanne, Weng, Onglee, Sager, Philip T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973962/
https://www.ncbi.nlm.nih.gov/pubmed/29603015
http://dx.doi.org/10.1007/s00280-018-3564-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973962/
https://www.ncbi.nlm.nih.gov/pubmed/29603015
http://dx.doi.org/10.1007/s00280-018-3564-1

Ejemplares similares